member
famili
filovirida
includ
ebola
viru
ebov
marburg
viru
marv
caus
sever
hemorrhag
fever
human
nonhuman
primat
casefat
human
rang
date
human
outbreak
ebov
trace
equatori
africa
danger
geograph
widespread
outbreak
ebov
infect
human
record
occur
west
africa
new
ebov
outbreak
declar
may
eastern
democrat
republ
congo
central
africa
week
western
outbreak
countri
notabl
increas
travel
led
import
ebov
marv
nonendem
area
around
globe
sever
potenti
vaccin
candid
move
clinic
trial
includ
pseudotyp
vesicular
stomat
viru
express
ebov
glycoprotein
egpvsv
base
vaccin
howev
current
neither
vaccin
postexposur
treatment
fdaapprov
combat
filovir
infect
given
high
lethal
comprehens
understand
filovir
pathogenesi
develop
novel
mechanismbas
prophylact
therapeut
countermeasur
urgent
need
filovirus
seem
target
immun
system
vascular
endothelia
caus
sever
form
viral
hemorrhag
fever
vhf
filovir
infect
initi
diffus
vascular
endothelium
dysfunct
mark
bleed
fluid
distribut
disord
dissemin
intravascular
coagul
dic
lead
organ
failur
latter
stage
diseas
vascular
endothelium
monolay
cell
line
blood
vessel
physiolog
condit
endothelium
play
pivot
role
provid
proper
hemostat
balanc
dysregul
barrier
form
endothelium
increas
vascular
permeabl
caus
hypotens
shock
syndrom
seen
mani
fatal
diseas
includ
vhf
case
howev
mechan
trigger
endothelium
disrupt
ebov
infect
still
fulli
understood
exploit
host
signal
pathway
effect
virul
strategi
employ
number
viral
hemorrhag
fever
pathogen
cyclic
adenosin
monophosph
camp
common
secondari
ubiquit
messeng
involv
sever
cellular
process
camp
translat
environment
signal
downstream
effect
multipl
cellular
level
mani
pathogen
develop
strategi
modul
camp
level
within
host
cell
includ
vascular
endothelium
hijack
host
cell
machineri
benefit
variou
stage
life
cycl
includ
entri
intern
fusion
replic
releas
howev
known
filovirus
employ
similar
strategi
effect
camp
transduc
two
key
ubiquit
express
intracellular
camp
receptor
campdepend
protein
kinas
pka
recent
identifi
exchang
protein
directli
activ
camp
epac
epac
activ
trigger
intern
conform
chang
induc
direct
bind
camp
lead
activ
downstream
signal
effect
two
known
mammalian
isoform
epac
encod
independ
gene
differ
tissu
express
pattern
isoform
express
within
vascular
endotheli
cell
ec
act
independ
pka
regul
mani
cellular
function
induc
camp
includ
vascular
barrier
function
endotheli
permeabl
cell
adhes
junction
microtubul
dynam
cytokin
signal
suppress
exocytosi
vitro
studi
suggest
pretreat
epacspecif
inhibitor
esi
induc
antimiddl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
activ
celltyp
independ
manner
howev
role
epac
filovir
infect
remain
unknown
present
studi
took
advantag
recent
develop
ex
vivo
vascular
cultur
method
vitro
mous
brain
microvascular
endotheli
cell
bmec
model
isol
mous
reveal
gene
delet
protect
vasculatur
infect
ebov
see
supplement
materi
genbank
access
number
importantli
pharmacolog
inhibit
use
anoth
esi
mimick
phenotyp
ex
vivo
model
esi
treatment
dramat
decreas
ebov
infect
ex
vivo
vasculatur
bmec
isol
wildtyp
mice
furthermor
postexposur
protect
ec
ebov
infect
confer
pharmacolog
inactiv
use
esi
employ
egpvsv
resembl
ebov
infect
show
reduc
egpvsv
infect
ec
nevertheless
activ
esa
render
ec
suscept
ebov
infect
pretreat
ultrastructur
studi
reveal
inactiv
block
egpvsv
intern
mechanist
studi
suggest
earli
stage
infect
activ
host
attenu
vitro
efficaci
egpvsv
infect
ec
data
strongli
suggest
play
critic
role
ebov
uptak
ec
mous
experi
perform
studi
carri
accord
nation
institut
health
unit
state
dept
agricultur
uam
divis
laboratori
anim
medicin
institut
anim
care
use
committe
iacuc
guidelin
protocol
support
studi
approv
utmb
iacuc
establish
ex
vivo
vascular
endotheli
cultur
model
ebov
infect
use
aortic
ring
isol
three
wildtyp
wt
three
mice
ko
also
known
mutant
mice
carri
conditionalreadi
allel
jackson
laboratori
stock
obtain
cross
germlin
cre
delet
mous
jackson
laboratori
stock
gener
knockout
mice
major
mice
use
experi
homozygot
wildtyp
control
incipi
congen
gener
heterozyg
intercross
similar
publish
model
mice
viabl
fertil
without
overt
abnorm
briefli
euthan
aorta
first
dissect
mice
clean
adipos
tissu
cut
five
ring
per
mous
aorta
total
aortic
ring
cultur
h
endotheli
cell
growth
medium
supplement
cell
applic
atlanta
ga
usa
volvol
fb
three
ring
per
mous
expos
ebov
plaqueform
unit
pfu
medium
one
well
cultur
plate
three
ring
mous
incub
uninfect
medium
microscop
evid
neocellular
growth
present
week
confirm
viabil
cultur
end
experi
aortic
ring
immersionfix
buffer
formalin
histolog
analysi
first
group
five
continu
section
tissu
section
aortic
ring
collect
store
process
use
immunofluoresc
reagent
detect
ebov
von
willebrand
factor
vwf
activ
purchas
tocri
bioscienc
avonmouth
bristol
unit
kingdom
pkaspecif
inhibitor
purchas
lc
laboratori
woburn
usa
esi
esa
synthes
dr
jia
zhou
laboratori
utmb
similar
epac
inhibitori
profil
slightli
potent
vitro
studi
human
umbil
vein
endotheli
cell
huvec
cell
applic
atlanta
ga
usa
human
cerebr
microvascular
endotheli
cell
hcmec
appli
biolog
materi
richmond
bc
canada
expos
medium
design
time
prior
downstream
experi
medium
dimethyl
sulfoxid
dmso
volvol
use
vehicl
control
activ
cell
stimul
h
determin
effect
huvec
viabil
vitro
cytotox
determin
use
mt
assay
kit
cultur
huvec
serial
dilut
separ
h
untreat
huvec
serv
control
absorb
nm
record
use
biotek
plate
reader
biotek
winooski
vt
usa
result
present
mean
standard
error
mean
three
independ
experi
experi
conduct
triplic
cell
cultur
prepar
describ
inocul
ebov
moi
min
time
fresh
media
ad
infect
cell
incub
environ
h
cell
media
infect
cell
inactiv
use
tripur
isol
reagent
sigma
aldrich
st
loui
mo
usa
store
rna
extract
immunofluoresc
stain
cell
fix
neutralbuff
formalin
bind
assay
dmso
huvec
incub
egpvsv
moi
min
ice
incub
period
unbound
virus
remov
wash
three
time
icecold
pb
membranebound
viral
particl
retriev
follow
freezethaw
cycl
equal
amount
fb
supplement
dmem
viral
sampl
store
downstream
assay
huvec
pretreat
dmso
infect
egpvsv
moi
h
thoroughli
wash
pb
earli
endosom
isol
cell
membran
fraction
perform
use
endosom
isol
cell
fraction
kit
invent
biotechnolog
eden
prairi
mn
usa
accord
manufactur
instruct
result
fraction
resuspend
tripur
rna
extract
ripa
buffer
immunoblot
puriti
earli
endosom
membran
fraction
verifi
immunoblot
antibodi
rais
earli
endosomespecif
membranespecif
na
k
atpas
protein
respect
dualtarget
stain
vwf
ebov
mous
aortic
ring
ultra
v
block
normal
rabbit
serum
dako
employ
reduct
nonspecif
background
vwf
antigenlabel
respect
deparaffin
rehydr
section
incub
antivwf
rabbit
polyclon
antibodi
h
follow
alexafluor
goat
antirabbit
igg
invitrogen
carlsbad
ca
usa
min
ebov
antigen
tissu
visual
afterward
incub
dylight
microscal
antibodi
label
kit
label
antiebov
rabbit
polyclon
antibodi
h
nuclei
counterstain
dapi
fluoresc
imag
analyz
use
olympu
epifluoresc
olympu
corpor
tokyo
japan
nikon
eclips
ti
confoc
microscop
nikon
tokyo
japan
quantit
viral
antigenposit
cytopath
effect
cpe
cell
fix
buffer
formalin
stain
detect
viral
antigen
fix
cell
monolay
incub
antiebov
rabbit
polyclon
antibodi
nuclei
counterstain
dapi
cell
examin
imag
captur
olympu
imag
system
use
final
optic
zoom
number
viral
antigenposit
foci
vapf
detect
microscop
field
manual
enumer
repres
imag
pleas
see
figur
result
express
number
vapf
microscop
field
ten
microscop
field
examin
experi
data
repres
least
three
experi
statist
signific
determin
use
student
ttest
oneway
analysi
varianc
result
regard
signific
twotail
p
valu
data
express
mean
standard
error
mean
gener
ex
vivo
vasculatur
model
use
aortic
ring
isol
ko
wt
mice
use
examin
ebov
infect
h
postexposur
ebov
observ
endothelium
aortic
ring
ko
mice
protect
infect
compar
infect
aortic
ring
isol
wt
mice
p
figur
b
figur
observ
valid
vitro
ebov
infect
model
mous
bmec
prepar
ko
wt
mice
infect
ebov
moi
figur
effici
infect
assess
realtim
pcr
qpcr
determin
number
copi
viral
rna
cell
figur
media
figur
format
viral
antigenposit
foci
vapf
detect
stain
infect
monolay
figur
p
result
demonstr
delet
gene
endotheli
cell
significantli
reduc
ebov
infect
esi
wide
employ
epac
biolog
research
given
isoform
express
within
ec
potenti
use
epac
pharmacolog
inhibit
protect
strategi
combat
endotheli
ebov
infect
explor
first
huvec
pretreat
dmso
vehicl
h
challeng
ebov
h
shown
figur
exposur
significantli
reduc
viral
load
cell
figur
cell
media
figur
well
cell
media
exposur
figur
p
h
postinfect
pi
compar
vehicletr
group
similar
inhibitori
effect
confirm
examin
format
vapf
cell
monolay
pretreat
either
indic
cytopath
effect
figur
figur
p
furthermor
viral
infect
confirm
use
assay
determin
infecti
titer
viru
media
figur
p
electron
microscopi
em
also
perform
huvec
pretreat
either
dmso
subsequ
infect
ebov
directli
visual
ebov
particl
figur
h
pi
viral
particl
figur
cell
figur
hardli
visibl
wherea
numer
ebov
particl
differ
stage
infect
dmsotreat
group
figur
found
figur
b
e
figur
pretreat
produc
dosedepend
effect
ebov
infect
ec
highest
protect
observ
concentr
p
notic
even
lowest
concentr
test
pretreat
reduc
viral
load
p
figur
c
importantli
esimedi
inhibitori
effect
ebov
infect
result
drugmedi
cytotox
figur
determin
whether
inhibit
classic
camppka
signal
pathway
also
protect
ec
ebov
infect
huvec
pretreat
specif
inhibitor
infect
ebov
h
pi
protect
effect
observ
cell
compar
vehicletr
group
figur
b
result
indic
play
import
role
ebov
infect
ec
affect
viral
infect
independ
classic
pka
signal
pathway
efficaci
experiment
ec
model
also
evalu
similar
experi
use
hcmec
bmec
wt
mice
perform
shown
figur
b
reduc
ebov
infect
observ
also
ec
p
order
rule
effect
limit
ebov
similar
experi
perform
marv
see
supplement
materi
genbank
access
number
anoth
highli
virul
member
famili
filovirida
found
compar
vehicl
group
treatment
huvec
infect
marv
also
attenu
format
vapf
figur
reduc
number
viral
rna
copi
media
h
pi
figur
p
assess
whether
postexposur
protect
ec
ebov
infect
confer
pharmacolog
inactiv
huvec
treat
h
infect
ebov
moi
h
pi
decreas
viral
load
cell
treat
p
p
figur
cell
cultur
medium
cell
treat
p
p
figur
observ
compar
vehicletr
group
similar
inhibitori
effect
confirm
observ
decreas
format
vapf
cell
monolay
posttreat
p
figur
data
support
pharmacolog
inactiv
impart
postexposur
effect
ebov
infect
ec
dissect
cellular
mechan
involv
filovir
infect
egpvsv
mimic
ebov
infect
employ
first
experi
perform
use
treatment
condit
describ
ebov
previous
huvec
pretreat
dmso
infect
egpvsv
moi
incub
h
efficaci
evalu
qpcr
shown
figur
pretreat
significantli
protect
cell
egpvsv
infect
p
wherea
vehicletr
cell
remain
highli
suscept
infect
pretreat
increas
infect
significantli
interestingli
howev
treatment
combin
challeng
egpvsv
restor
viral
infect
huvec
p
figur
identifi
stage
ebov
life
cycl
affect
inactiv
dmsopretr
huvec
inocul
egpvsv
moi
h
examin
em
figur
huvec
pretreat
dmso
observ
egpvsv
trigger
cell
membran
ruffl
enter
cell
mostli
macropinocytosislik
pathway
em
studi
also
show
singl
agglomer
egpvsv
particl
vesicular
compart
figur
contrast
huvec
pretreat
egpvsv
particl
observ
surfac
cell
membran
figur
g
egpvsv
particl
rare
observ
macropinocytosislik
process
egpvsv
particl
found
vesicular
compart
data
suggest
inactiv
affect
earli
stage
viral
infect
rather
later
fusion
replic
stage
examin
whether
affect
viral
bind
ec
viru
bind
assay
perform
incub
dmso
huvec
egpvsv
moi
min
allow
viral
particl
bind
cell
surfac
bound
virus
analyz
qpcr
shown
figur
number
viral
rna
copi
membranebound
viral
particl
detect
group
significantli
differ
compar
vehiclepretr
group
result
suggest
inactiv
signific
effect
ebov
bind
ec
surfac
better
defin
inhibitori
effect
ebov
infect
measur
number
egpvsv
rna
copi
present
membran
earli
endosom
fraction
huvec
grown
flask
pretreat
dmso
incub
egpvsv
moi
h
rins
thoroughli
process
membran
earli
endosom
fraction
respect
figur
membran
fraction
viral
rna
detect
group
reveal
signific
differ
figur
wherea
viral
rna
detect
earli
endosom
fraction
group
expect
viral
rna
found
earli
endosom
fraction
vehicletr
group
p
figur
result
confirm
viral
rna
copi
detect
earli
endosom
compart
ec
follow
inactiv
taken
togeth
data
suggest
affect
earli
stage
ebov
infect
occur
initi
viral
bind
cell
surfac
format
earli
endosom
includ
virus
earlier
studi
shown
famili
relat
intracellular
signal
transduc
enzym
capabl
phosphoryl
hydroxyl
group
inositol
ring
critic
entri
ebov
document
suppress
akt
phosphoryl
confirm
ec
model
figur
evalu
effect
infect
inactiv
incub
huvec
activ
h
challeng
egpvsv
activ
ec
significantli
reduc
protect
efficaci
compar
group
receiv
figur
p
determin
qpcr
assess
viral
rna
copi
number
treatment
significantli
affect
viral
load
vehiclepretr
group
taken
togeth
data
suggest
regul
ebov
entri
may
requir
involv
signal
pathway
major
envelop
virus
depend
endocytosi
entri
viral
glycoprotein
gp
mediat
viral
uptak
endocytosi
membran
fusion
provid
opportun
exploit
potenti
druggabl
target
control
filoviru
entri
cell
signific
insight
gain
intens
studi
mechan
underli
membran
fusion
filoviru
endocyt
vesicl
introduc
viru
genom
cytoplasm
subsequ
step
viral
replic
cycl
carri
howev
earlier
event
ebov
uptak
endocytosi
viru
fulli
enter
cell
remain
enigmat
ec
play
import
role
pathogenesi
lethal
filovir
infect
use
ex
vivo
vitro
model
demonstr
delet
gene
inactiv
esi
nontox
concentr
significantli
attenu
ebov
infect
vasculatur
ec
activ
use
esa
restor
ebov
infect
ec
combin
distinct
independ
approach
found
inactiv
block
filovir
uptak
experi
present
suggest
pathwaymedi
filovir
endocytosi
target
pharmacolog
manipul
campepac
system
activ
ec
significantli
reduc
protect
efficaci
significantli
affect
viral
infect
vehicletr
group
observ
suggest
govern
ebov
uptak
ec
present
report
first
studi
reveal
involv
campepac
signal
pathway
entri
envelop
virus
importantli
campepac
signal
axi
exploit
potenti
target
develop
compound
control
filovir
infect
find
intracellular
camp
receptor
epac
import
ebov
infect
ec
consist
previou
report
regard
role
epac
intracellular
pathogen
infect
one
studi
recent
demonstr
merscov
sarscov
requir
viral
replic
pretreat
exert
antivir
effect
epitheli
cell
line
infect
merscov
previous
report
delet
gene
protect
mice
lethal
dose
spot
fever
group
rickettsia
oblig
intracellular
bacteria
studi
inhibit
suppress
bacteri
adhes
invas
taken
togeth
data
provid
strong
link
host
campepac
signal
axi
intracellular
pathogen
infect
previou
studi
use
camppkaspecif
inhibitor
demonstr
hepat
c
viru
exploit
camppka
signal
system
facilit
entri
infect
determin
whether
classic
camp
signal
critic
involv
ebov
infect
ec
huvec
pretreat
camppkaspecif
inhibitor
infect
ebov
protect
effect
observ
result
confirm
play
import
role
ec
ebov
infect
affect
viral
infect
independ
classic
camppka
signal
pathway
initi
encount
ebov
ec
occur
plasma
membran
ebov
must
adher
cell
surfac
trigger
host
endocyt
plasma
membran
dynam
bind
host
surfac
ebov
virion
interact
variou
cell
membran
molecul
includ
nonspecif
receptor
two
type
nonspecif
receptor
identifi
ctype
lectin
phosphatidylserin
receptor
present
studi
viral
bind
assay
use
egpvsv
show
signific
differ
dmso
huvec
suggest
ebov
bind
endotheli
surfac
manner
howev
ultrastructur
experi
reveal
egpvsv
intern
ec
via
macropinocytosi
manner
find
compat
previou
studi
show
campepac
signal
pathway
requir
regul
compartment
endosom
importantli
inactiv
dramat
reduc
number
viral
rna
copi
earli
endosom
compart
suggest
potenti
target
control
ebov
infect
ec
use
esi
owe
gener
larg
size
filament
particl
virus
predominantli
taken
macropinocytosi
classic
clathrin
caveolin
phagocytosismedi
endocytosi
critic
involv
find
em
studi
demonstr
inactiv
abrog
creation
egpvsvinduc
macropinocytosi
form
ruffl
region
endotheli
plasma
membran
suggest
ebov
gpmediat
viru
uptak
requir
involv
host
signal
pathway
mani
intracellular
pathogen
exploit
host
cell
signal
pathway
facilit
entri
howev
deeper
insight
requir
cell
signal
pathway
ebov
uptak
remain
scarc
one
current
view
ebov
uptak
cholesterolrich
lipid
raft
host
plasma
membran
serv
import
platform
use
ebov
enter
cell
although
least
abund
phospholipid
cell
membran
phosphatidylinositol
one
versatil
signal
molecul
cell
play
import
role
endocytosi
play
wellcharacter
role
macropinocytosi
orchestr
signal
cytoskelet
modul
protrus
extens
closur
macropinosom
format
activ
observ
upon
viru
bind
number
infect
model
envelop
virus
ebov
induc
intern
host
cell
viral
gptrigger
entri
mechan
employ
signal
pathway
consid
activ
epac
stimul
signal
pathway
conceiv
may
regul
ebov
uptak
modul
cellular
signal
system
known
regul
aforement
cellular
function
precis
molecular
mechan
control
ebov
entri
clear
research
understand
signal
crosstalk
signal
pathway
hijack
ebov
macropinocytosi
current
ongo
observ
postexposur
protect
ec
ebov
infect
confer
pharmacolog
inactiv
biolog
basi
cellular
level
remain
unclear
use
ex
vivo
model
detect
sporad
ebov
viral
antigen
signal
coloc
ecspecif
marker
vwf
along
tunica
intima
aortic
ring
h
pi
figur
use
microscopi
measur
number
vapf
ebovinfect
cell
monolay
h
pi
viral
antigenposit
ec
detect
cell
cluster
viral
antigen
visual
cell
surround
vapf
appear
ebov
replic
ec
cluster
rather
neighbor
cell
monolay
suggest
window
follow
initi
infect
ec
cluster
protect
neighbor
cell
viral
infect
howev
futur
observ
longer
period
time
postinfect
provid
accur
inform
support
potenti
postexposur
protect
confer
esi
vivo
examin
provid
addit
data
support
hypothesi
esi
could
use
develop
therapeut
strategi
filovir
infect
despit
signific
progress
develop
camp
analogu
epac
agonist
epac
isoform
select
camp
analogu
potenti
offtarget
effect
molecul
camp
phosphodiesteras
remain
challeng
technic
sinc
camp
analogu
bioactiv
esteras
cell
cultur
without
sera
see
http
wwwbiologdemediatechinfoc
restrict
applic
use
primari
endotheli
cell
famili
novel
noncamp
agonist
develop
repres
firstinclass
isoformselect
activ
compound
potenti
suppress
proinflammatori
cytokin
signal
therebi
reduc
risk
side
effect
associ
gener
campelev
agent
activ
multipl
respons
pathway
one
agonist
esa
employ
studi
display
capabl
exert
pharmacolog
effect
complet
ec
cultur
medium
induc
enhanc
egpvsv
infect
huvec
therebi
support
import
role
play
ebov
infect
nevertheless
limit
present
studi
elucid
exact
mechan
underli
inactiv
attenu
ebov
infect
ec
first
ex
vivo
model
allow
us
perform
compar
studi
wt
ko
group
howev
mimic
complic
host
respons
context
vivo
infect
second
nonmouseadapt
ebola
viru
use
ex
vivo
mous
model
may
directli
translat
vivo
applic
sinc
wildtyp
viru
pathogen
mice
third
histolog
requir
includ
appropri
orient
aortic
ring
embed
show
intima
layer
microtomi
effect
antigen
retriev
stain
make
difficult
optim
ecspecif
stain
vwf
last
measur
level
phosphoryl
vehicl
group
provid
indirect
evid
support
hypothesi
signal
system
involv
mechan
underli
protect
ebov
infect
via
inactiv
accur
mechan
yet
elucid
conclus
studi
combin
vitro
primari
human
endotheli
system
ex
vivo
model
reveal
novel
role
ebov
infect
vascular
ec
govern
ebov
intern
via
regul
pathwaymedi
filovir
macropinocytosi
deeper
insight
gain
futur
vivo
studi
use
mous
model
ebov
infect
vivo
efficaci
test
esi
use
wildtyp
mous
model
filovir
infect
futur
studi
hope
pave
way
toward
develop
novel
broadspectrum
antivir
therapeut
combat
filovir
infect
